STOCK TITAN

Immunome Inc. (IMNM) grants CTO 76,500 stock options and 38,250 RSUs

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Immunome Inc. reported equity awards to Chief Technical Officer Philip Tsai on July 23, 2026. Tsai received 76,500 stock options at a $22.01 exercise price expiring in 2036 and 38,250 RSUs, all vesting over time contingent on his continuous service, bringing reported direct holdings to 81,550 common shares/RSUs.

Positive

  • None.

Negative

  • None.
Insider Tsai Philip
Role Chief Technical Officer
Type Security Shares Price Value
Grant/Award Employee Stock Option (right to buy) F2 76,500 $0.00 $0.00
Grant/Award Common Stock F1 38,250 $0.00 $0.00
Holdings After Transaction: Employee Stock Option (right to buy) — 76,500 shares (Direct); Common Stock — 81,550 shares (Direct)
Footnotes (2)
  1. F1. Represents the number of shares of the Issuer's common stock ("Common Stock") underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date.
  2. F2. 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.
Stock options granted 76,500 Employee Stock Option grant to CTO Philip Tsai on July 23, 2026
Option exercise price $22.01 per share Exercise price for 76,500 options granted July 23, 2026
Option expiration date 2036-07-22 Expiration date of Employee Stock Option grant
RSUs granted 38,250 Number of RSUs awarded to Philip Tsai on July 23, 2026
Direct holdings after RSU award 81,550 Total Common Stock/RSUs reported as directly owned after July 23, 2026 award
RSU annual vesting tranche 25% Portion of RSUs vesting each year on grant-date anniversaries, subject to continuous service
Initial option vesting tranche 25% Portion of options vesting on July 23, 2027, subject to continuous service
restricted stock units ("RSUs") financial
"Represents the number of shares of the Issuer's common stock ("Common Stock") underlying restricted stock units ("RSUs")."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Employee Stock Option (right to buy) financial
"Security title reported as Employee Stock Option (right to buy) with underlying Common Stock."
continuous service financial
"subject to the Reporting Person's continuous service through each such vesting date."
vesting date financial
"shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date."

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What equity awards did Immunome (IMNM) grant to CTO Philip Tsai?

Philip Tsai received 76,500 stock options at a $22.01 exercise price and 38,250 RSUs from Immunome. The awards were granted on July 23, 2026 and vest over several years, subject to his continuous service with the company.

What is the vesting schedule for Philip Tsai’s new IMNM stock options?

The options vest 25% on July 23, 2027, with one‑thirty‑sixth of the remaining shares vesting monthly thereafter. All vesting is contingent on Tsai’s continuous service through each applicable vesting date.

How do Philip Tsai’s new IMNM RSUs vest over time?

The 38,250 RSUs vest and settle into Common Stock in 25% increments on each anniversary of the grant date. Each vesting tranche requires Tsai to remain in continuous service through the relevant vesting date.

How many Immunome (IMNM) shares or RSUs does Philip Tsai hold after these awards?

After the RSU award, Tsai is reported as directly owning 81,550 shares/RSUs of Immunome Common Stock. This figure reflects his position following the July 23, 2026 grant described in the insider transaction report.

Were Philip Tsai’s IMNM equity grants made under a Rule 10b5-1 trading plan?

The filing’s Rule 10b5‑1 checkbox is not marked as affirmatively adopted, indicating these awards are not reported as executed under a Rule 10b5‑1 trading plan. They are characterized as grant or award acquisitions.

What are the key terms of Philip Tsai’s new IMNM stock options?

Tsai’s options cover 76,500 shares of Common Stock at a $22.01 exercise price and expire on July 22, 2036. Vesting is time‑based, with an initial 25% vesting after one year, then monthly vesting thereafter.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Tsai Philip

(Last)(First)(Middle)
C/O IMMUNOME, INC.
18702 N. CREEK PARKWAY, SUITE 100

(Street)
BOTHELL WASHINGTON 98011

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Immunome Inc. [ IMNM ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Technical Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/23/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/23/2026A38,250(1)A$081,550D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option (right to buy)$22.0107/23/2026A76,500 (2)07/22/2036Common Stock76,500$076,500D
Explanation of Responses:
1. Represents the number of shares of the Issuer's common stock ("Common Stock") underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date.
2. 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.
/s/ Sandra Stoneman, Attorney-in-Fact07/27/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)